Total Payments
$1,177
2024 Payments
$445.23
Companies
16
Transactions
37
Medicare Patients
1,860
Medicare Billing
$305,938
Payment Breakdown by Category
Food & Beverage$1,174 (99.7%)
Education$3.08 (0.3%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $1,174 | 36 | 99.7% |
| Education | $3.08 | 1 | 0.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $256.42 | 7 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $238.79 | 8 | $0 (2024) |
| Mallinckrodt Hospital Products Inc. | $131.01 | 1 | $0 (2024) |
| INTERCEPT PHARMACEUTICALS, INC. | $116.83 | 1 | $0 (2022) |
| Otsuka America Pharmaceutical, Inc. | $102.92 | 4 | $0 (2024) |
| Horizon Therapeutics plc | $74.88 | 3 | $0 (2023) |
| Vifor Pharma, Inc. | $53.96 | 2 | $0 (2024) |
| Bayer HealthCare Pharmaceuticals Inc. | $39.90 | 2 | $0 (2022) |
| Amgen Inc. | $30.58 | 2 | $0 (2024) |
| Alexion Pharmaceuticals, Inc. | $24.68 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $445.23 | 15 | Mallinckrodt Hospital Products Inc. ($131.01) |
| 2023 | $344.10 | 14 | AstraZeneca Pharmaceuticals LP ($191.33) |
| 2022 | $247.20 | 6 | INTERCEPT PHARMACEUTICALS, INC. ($116.83) |
| 2018 | $66.86 | 1 | Novartis Pharmaceuticals Corporation ($66.86) |
| 2017 | $73.81 | 1 | Novartis Pharmaceuticals Corporation ($73.81) |
All Payment Transactions
37 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/09/2024 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $21.68 | General |
| 12/07/2024 | CALLIDITAS THERAPEUTICS US INC. | TARPEYO (Drug) | Food and Beverage | In-kind items and services | $23.97 | General |
| Category: Nephrology | ||||||
| 12/05/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $17.07 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/05/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $13.51 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/03/2024 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $18.09 | General |
| 11/13/2024 | Otsuka America Pharmaceutical, Inc. | JYNARQUE (Drug) | Food and Beverage | In-kind items and services | $22.81 | General |
| Category: NEPHROLOGY | ||||||
| 11/11/2024 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $21.50 | General |
| 09/12/2024 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $25.63 | General |
| 04/24/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $20.63 | General |
| Category: Diabetes | ||||||
| 04/16/2024 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $28.85 | General |
| 03/29/2024 | Ardelyx, Inc. | IBSRELA (Drug) | Food and Beverage | In-kind items and services | $24.41 | General |
| Category: GASTROENTEROLOGY | ||||||
| 03/07/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $23.16 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 02/08/2024 | Mallinckrodt Hospital Products Inc. | TERLIVAZ (Drug) | Food and Beverage | In-kind items and services | $131.01 | General |
| Category: CRITICAL CARE | ||||||
| 01/26/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $24.30 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 01/08/2024 | Vifor Pharma, Inc. | — | Food and Beverage | In-kind items and services | $28.61 | General |
| 12/05/2023 | Travere Therapeutics, Inc. | — | Education | In-kind items and services | $3.08 | General |
| 09/19/2023 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $24.68 | General |
| Category: Rare Disease | ||||||
| 08/28/2023 | Otsuka America Pharmaceutical, Inc. | JYNARQUE (Drug) | Food and Beverage | In-kind items and services | $26.21 | General |
| Category: NEPHROLOGY | ||||||
| 08/23/2023 | Merck Sharp & Dohme LLC | PREVYMIS (Drug) | Food and Beverage | In-kind items and services | $20.44 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 08/18/2023 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $15.85 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 08/15/2023 | Horizon Therapeutics plc | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $12.98 | General |
| Category: KRYSTEXXA | ||||||
| 06/22/2023 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $12.87 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 04/29/2023 | Horizon Therapeutics plc | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $13.49 | General |
| Category: KRYSTEXXA | ||||||
| 04/20/2023 | Vifor Pharma, Inc. | Veltassa (Drug), Korsuva | Food and Beverage | In-kind items and services | $25.35 | General |
| Category: Hyperkalemia | ||||||
| 03/23/2023 | Otsuka America Pharmaceutical, Inc. | JYNARQUE (Drug) | Food and Beverage | In-kind items and services | $26.54 | General |
| Category: NEPHROLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 16 | 616 | 1,328 | $268,233 | $95,741 |
| 2022 | 6 | 399 | 522 | $78,090 | $43,673 |
| 2021 | 10 | 467 | 864 | $250,547 | $92,948 |
| 2020 | 11 | 378 | 766 | $224,990 | $73,575 |
Total Patients
1,860
Total Services
3,480
Medicare Billing
$305,938
Procedure Codes
45
All Medicare Procedures & Services
45 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 157 | 321 | $73,974 | $25,092 | 33.9% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 72 | 196 | $29,033 | $11,459 | 39.5% |
| 99490 | Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 70 | 226 | $26,578 | $9,542 | 35.9% |
| 90961 | Dialysis services, 2-3 physician visits per month (20 years or older) | Office | 2023 | 12 | 43 | $23,819 | $8,873 | 37.3% |
| 90966 | Home dialysis services per month (20 years or older) | Office | 2023 | 20 | 41 | $22,646 | $8,780 | 38.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 42 | 87 | $28,621 | $7,872 | 27.5% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 23 | 61 | $13,471 | $5,416 | 40.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 39 | 39 | $11,639 | $4,050 | 34.8% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 29 | 29 | $10,290 | $3,624 | 35.2% |
| 99439 | Chronic care management services for two or more chronic conditions, additional 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 69 | 72 | $6,295 | $2,525 | 40.1% |
| 99457 | Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | Office | 2023 | 13 | 68 | $6,149 | $2,436 | 39.6% |
| 99454 | Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | Office | 2023 | 11 | 67 | $6,056 | $2,392 | 39.5% |
| 90935 | Hemodialysis procedure with physician evaluation | Facility | 2023 | 22 | 41 | $5,672 | $2,146 | 37.8% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 14 | 14 | $3,448 | $1,337 | 38.8% |
| 99453 | Remote monitoring of physiologic parameters, initial set-up and patient education on use of equipment | Office | 2023 | 11 | 11 | $444.40 | $149.16 | 33.6% |
| 81000 | Manual urinalysis test with examination using microscope, non-automated | Office | 2023 | 12 | 12 | $96.48 | $47.28 | 49.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 129 | 198 | $26,334 | $18,404 | 69.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 96 | 96 | $21,120 | $10,677 | 50.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 26 | 41 | $7,913 | $5,387 | 68.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 32 | 32 | $8,928 | $4,661 | 52.2% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 41 | 80 | $11,920 | $4,245 | 35.6% |
| 81000 | Manual urinalysis test with examination using microscope, non-automated | Office | 2022 | 75 | 75 | $1,875 | $298.10 | 15.9% |
| 90960 | Dialysis services (4 or more physician visits per month), patient 20 years of age and older | Office | 2021 | 16 | 111 | $67,710 | $30,455 | 45.0% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 78 | 173 | $37,541 | $13,230 | 35.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 111 | 164 | $35,424 | $12,095 | 34.1% |
About Dr. Melissa Anderson, MD
Dr. Melissa Anderson, MD is a Nephrology healthcare provider based in Indianapolis, Indiana. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/11/2008. The National Provider Identifier (NPI) number assigned to this provider is 1871753152.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Melissa Anderson, MD has received a total of $1,177 in payments from pharmaceutical and medical device companies, with $445.23 received in 2024. These payments were reported across 37 transactions from 16 companies. The most common payment nature is "Food and Beverage" ($1,174).
As a Medicare-enrolled provider, Anderson has provided services to 1,860 Medicare beneficiaries, totaling 3,480 services with total Medicare billing of $305,938. Data is available for 4 years (2020–2023), covering 45 distinct procedure/service records.
Ad
Practice Information
- Specialty Nephrology
- Location Indianapolis, IN
- Active Since 06/11/2008
- Last Updated 05/31/2022
- Taxonomy Code 207RN0300X
- Entity Type Individual
- NPI Number 1871753152
Products in Payments
- FARXIGA (Drug) $238.79
- ZORTRESS (Drug) $140.67
- TERLIVAZ (Drug) $131.01
- OCALIVA (Drug) $116.83
- KRYSTEXXA (Biological) $105.46
- JYNARQUE (Drug) $102.92
- Kerendia (Drug) $39.90
- Veltassa (Drug) $25.35
- ULTOMIRIS (Biological) $24.68
- IBSRELA (Drug) $24.41
- TARPEYO (Drug) $23.97
- Ozempic (Drug) $20.63
- PREVYMIS (Drug) $20.44
- GATTEX (Drug) $14.70
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Nephrology Doctors in Indianapolis
Rajiv Agarwal, M.d, M.D
Nephrology — Payments: $1.8M
Nephrology $1.8M
Jay Wish, Md, MD
Nephrology — Payments: $612,981
Nephrology $612,981
Bruce Molitoris, M.d, M.D
Nephrology — Payments: $155,177
Nephrology $155,177
Allon Friedman, M.d, M.D
Nephrology — Payments: $118,706
Nephrology $118,706
Dr. Arjun Sinha, M.d, M.D
Nephrology — Payments: $103,353
Nephrology $103,353
Sharon Moe, M.d, M.D
Nephrology — Payments: $40,018
Nephrology $40,018